Thermo Fisher Scientific Solution Detects Anabolic Androgenic Steroids in Horse Biological Fluids
News Feb 17, 2009
Thermo Fisher Scientific Inc. has announced the success of its liquid chromatography tandem mass spectrometry (LC-MS/MS) solution at the Kenneth L. Maddy Analytical Chemistry Laboratory.
The Thermo Scientific Aria TLX-2 turbulent flow chromatography system coupled with the Thermo Scientific TSQ Vantage triple stage quadrupole mass spectrometer was selected to perform detection of anabolic androgenic steroids (AAS) in urine and plasma samples from performance horses.
Based in Davis, California, the laboratory is the authorized equine drug-testing laboratory for California's six permanent race courses, nine seasonal fair venues and other performance events.
One of the major challenges when determining AAS in biological fluids is sample preparation. Endogenous phospholipids, present in extremely high levels in biological samples, are a major component of matrix interference. These interferences affect analyte ionization, reducing the precision and reproducibility of subsequent quantitative MS analysis (ion suppression).
Equine testing laboratories have traditionally used immunoassay screening followed by gas chromatography/mass spectrometry (GC/MS) confirmation to minimize interferences. However, these methods lack sensitivity, require lengthy sample preparation and do not remove all matrix interferences.
The Kenneth L. Maddy Analytical Chemistry Laboratory required a means of analysis with high accuracy and simple sample preparation to cater for the vast number of incoming samples. Dr. Scott Stanley, Associate Professor of Analytical Chemistry and Pharmacology and head of the laboratory, decided to invest in a comprehensive Thermo Scientific solution combining an Aria TLX-2 system utilizing Thermo Scientific TurboFlow technology with a TSQ Vantage triple stage quadrupole mass spectrometer.
Researchers have been able to detect very small quantities (low parts per trillion) of substances in blood long after an illegal administration. The labor-intensive SPE and LLE procedures have been eliminated.
Synthetic biologists look to re-engineer cells to make complex molecules for specific needs, including pharmaceuticals. But the trial-and-error process is difficult and time-consuming. Now, by combining two state-of-the-art research approaches, researchers have created a fast, efficient way to engineer and analyze metabolic pathways.READ MORE